Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

antineoplaston AS 2-1 4antineoplaston A10 4Cyclophosphamide 4Cisplatin 4Temozolomide 3Radiotherapy 3dactolisib 2Vincristine 2Filgrastim 2Everolimus 2Etoposide 2Bevacizumab 2spartalizumab 1sargramostim 1pasireotide 1ganitumab 1gallium Ga 68 dotatate 1fosbretabulin 1cixutumumab 1belzutifan 1aldesleukin 1Topotecan 1Thiotepa 1TH 302 1Sunitinib 1Standard of Care 1Pregabalin 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neuroectodermal Tumors, Primitive × Everolimus × Clear all
NCT01374451 2016-12-20

COOPERATE-2

Novartis

Phase 2 Terminated
160 enrolled 17 charts
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡